Caprion Signs Biomarker ID Deal with Boehringer Ingelheim

Caprion Pharmaceuticals said this week that it has entered into a research collaboration with Boehringer Ingelheim to identify metabolic and inflammatory disease biomarkers using Caprion's CellCarta proteomics discovery platform.

Under the terms of the agreement, Caprion will identify pharmacodynamic markers in plasma resulting from the administration of pre-clinical pharmaceutical compounds, Caprion said.

Financial details of the agreement were not disclosed.